# Janssen Vaccines & Prevention

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/janssen-vaccines-prevention-b-v

- Industry: Pharmaceuticals
- Headquarters: Leiden, Netherlands
- Website: www.janssen.com
- Latest round: Seed (Jun 1, 1998)
- Investors on record: 1

## About

Janssen Vaccines & Prevention B.V. is a global company focused on research and development of innovative vaccines and prevention methods for infectious diseases. They aim to enhance public health through scientific advancements.Janssen Vaccines & Prevention B.V. specializes in developing vaccines to combat infectious diseases. Founded in 1993 and headquartered in Leiden, Netherlands, the company has evolved but has not undergone significant changes in its business strategy. It has completed a total of 10 deals, with its most recent deal on October 11, 2000, where Crucell listed on Euronext and NASDAQ under stock symbol CRXL. The latest funding round was a GRANT amounting to EUR 1.70 mn from the European Union.The company specializes in developing a diverse range of vaccines aimed at preventing infectious diseases. Their core offerings focus on innovative vaccine solutions designed to enhance health outcomes for individuals at risk of serious ailments. Janssen's products are available through partnerships with healthcare providers, hospitals, and specialty pharmacies, ensuring broad access across North America, Europe, and select markets in Asia-Pacific.In 2021, Janssen Vaccines & Prevention B.V. reported a revenue of EUR 664,157,513 and an EBITDA of EUR 179,035,451.4. Their revenue model primarily relies on sales of vaccines marketed through various channels, including direct agreements with healthcare institutions and collaborations with wholesalers for distribution.Janssen Vaccines & Prevention B.V. is focused on expanding its vaccine portfolio and is currently designing new products aimed at addressing emerging infectious diseases. The company seeks to enter new markets in Asia-Pacific by 2023 and is leveraging its most recent funding of EUR 1.70 mn to support these initiatives. Additionally, the firm aims to enhance its research capabilities and strengthen partnerships with healthcare entities to facilitate its product offerings.

## Funding rounds

- Seed, Jun 1, 1998 — EQT Life Sciences

## Investors

- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Seed